Biopsy-confirmed diffuse exanthematous drug eruption following tirzepatide initiation: A case report
Our Dermatology Online · 01.10.2026 · 4 (17)
DOI: 10.7241/ourd.20264.17 ↗Kurz gefasst
Fallbericht in der Zeitschrift Our Dermatology Online, online erschienen am 01.10.2026. Verfasst von Kanika Garg und 3 weiteren Autor:innen. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, is used to treat type 2 diabetes mellitus. While gastrointestinal adverse effects are well established, cutaneous manifestations are less characterized. We report a case of a biopsy-confirmed exanthematous drug eruption associated with tirzepatide. A 74-year-old woman developed profuse watery diarrhea and an intensely pruritic rash shortly after initiating tirzepatide. Over three weeks, the eruption involved the bilateral upper extremities and proximal lower extremities. Histopathologic evaluation revealed superficial dermal perivascular dermatitis with eosinophils and mild epidermal spongiosis. Discontinuation of tirzepatide and topical corticosteroids led to clinical improvement. This case expands the limited literature on systemic dermatologic adverse effects of tirzepatide by demonstrating a biopsy-confirmed exanthematous drug eruption. Recognition of such reactions allows for prompt diagnosis and enhanced patient counseling. This represents one of the first reported biopsy-confirmed exanthematous drug eruptions associated with tirzepatide. Key words: Tirzepatide, GLP-1 receptor agonist, Cutaneous adverse drug reaction, Obesity pharmacotherapy, Dermatologic toxicity
Zitieren
APA
Garg, K., J.Zhu, J., Sidgal, R., & M.Nazif, A. (2026). Biopsy-confirmed diffuse exanthematous drug eruption following tirzepatide initiation: A case report. Our Dermatology Online, 4(17). https://doi.org/10.7241/ourd.20264.17
Vancouver
Garg K, J.Zhu J, Sidgal R, M.Nazif A. Biopsy-confirmed diffuse exanthematous drug eruption following tirzepatide initiation: A case report. Our Dermatology Online. 2026;4(17). doi:10.7241/ourd.20264.17
BibTeX
@article{Garg2026,
author = {Garg, Kanika and J.Zhu, Joyce and Sidgal, Ritu and M.Nazif, Abdulrahman},
title = {Biopsy-confirmed diffuse exanthematous drug eruption following tirzepatide initiation: A case report},
journal = {Our Dermatology Online},
year = {2026},
volume = {4},
number = {17},
doi = {10.7241/ourd.20264.17}
}
EUVIMED